The US FDA's approval on 25 August of Shire's hereditary angioedema (HAE) drug Firazyr (icatibant) as the first and only self-administered subcutaneous treatment for acute attacks has not only opened the gate for the medicine to claim a favourable chunk of the US market in that indication, but also could have an impact on the prophylactic setting.
Will Shire's acute HAE drug OK shift dynamic for ViroPharma's prophylactic?
The US FDA's approval on 25 August of Shire's hereditary angioedema (HAE) drug Firazyr (icatibant) as the first and only self-administered subcutaneous treatment for acute attacks has not only opened the gate for the medicine to claim a favourable chunk of the US market in that indication, but also could have an impact on the prophylactic setting.
More from Alimentary/Metabolic
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Therapeutic Category
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.